来源：Gangtise投研

　　九源基因（02566.HK）2024年度业绩发布会：九源基因2024年度业绩发布会介绍了公司经营亮点与未来规划。公司营业收入达13.69亿人民币，同比增长6.4%，毛利率提升至79%，核心产品保持高增速，生物药近3~4年平均增幅21.7%。公司2024年上市，引入多家战略投资人，公众认购倍数超670倍。研发方面，2024年JY06获上市批准，JY54等多款在研产品聚焦骨科、代谢等领域，未来有望推出多款新品。商业化方面，骨诱导产品市场覆盖30个省，过去三年复合增长率超33%，司美格鲁肽等重点产品已布局院内、院外及海外市场。未来公司将持续拓展业务，提升市场份额，预计2025年营收增速达10%。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.